UroGen Pharma Ltd. (URGN)
Automate Your Wheel Strategy on URGN
With Tiblio's Option Bot, you can configure your own wheel strategy including URGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol URGN
- Rev/Share 1.9373
- Book/Share -0.9797
- PB -13.5148
- Debt/Equity -2.6895
- CurrentRatio 5.6471
- ROIC -0.5343
- MktCap 610463300.0
- FreeCF/Share -2.2646
- PFCF -5.6843
- PE -4.5356
- Debt/Assets 0.5046
- DivYield 0
- ROE -974.8662
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | URGN | H.C. Wainwright | Neutral | Buy | -- | $50 | June 16, 2025 |
| Downgrade | URGN | H.C. Wainwright | Buy | Neutral | -- | -- | May 22, 2025 |
| Initiation | URGN | Scotiabank | -- | Sector Outperform | -- | $23 | April 16, 2025 |
| Resumed | URGN | Ladenburg Thalmann | -- | Buy | -- | $31 | Feb. 19, 2025 |
| Initiation | URGN | Guggenheim | -- | Buy | -- | $40 | Aug. 22, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
Published: June 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ: URGN).
Read More
URGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered Losses
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ:URGN) and certain of the Company's senior executives for potential violations of the federal securities laws.
Read More
Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN
Published: June 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. ("UroGen Pharma Ltd." or the "Company") (NASDAQ: URGN) of a class action securities lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGN
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).
Read More
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky Before July 28, 2025 to Join Class Action
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=153300&wire=1&utm_campaign=12 or contact Joseph E.
Read More
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ: URGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read More
Did You Lose Money on UroGen Pharma Ltd. (URGN)? Levi & Korsinsky Urges Investors to Act Before July 28, 2025
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=153258&wire=1&utm_campaign=28 or contact Joseph E.
Read More
Class Action Filed Against UroGen Pharma Ltd. (URGN) Over Securities Violations - Contact Levi & Korsinsky Today
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=153059&wire=1&utm_campaign=29 or contact Joseph E.
Read More
URGN CLASS ACTION NOTICE: UroGen Pharma Ltd. Was Sued For Securities Fraud; Contact BFA Law if You Suffered Losses
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ:URGN) and certain of the Company's senior executives for potential violations of the federal securities laws.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN
Published: June 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. ("UroGen Pharma Ltd." or the "Company") (NASDAQ: URGN) of a class action securities lawsuit.
Read More
UroGen Pharma: Lessons Learned And Future Outlook
Published: June 13, 2025 by: Seeking Alpha
Sentiment: Positive
UroGen Pharma's FDA approval for UGN-102 removes existential risk and validates a contrarian investment stance, driving a sharp stock price recovery. A key investment thesis now hinges on UGN-102's commercial uptake, as physician adoption versus entrenched surgical standards remains uncertain. UroGen's financial runway is limited, with high cash burn and royalty obligations, raising the likelihood of future capital raises or non-dilutive financing.
Read More
URGN LAWSUIT ALERT: Levi & Korsinsky Notifies UroGen Pharma Ltd. Investors - Lead Plaintiff Deadline July 28, 2025
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=153039&wire=1&utm_campaign=7 or contact Joseph E.
Read More
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens Berman
Published: June 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025.
Read More
Investor Alert: Deadline Approaching to Join UroGen Pharma Ltd. (URGN) Class Action - Contact Levi & Korsinsky
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=153012&wire=1&utm_campaign=25 or contact Joseph E.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).
Read More
Did You Lose Money on UroGen Pharma Ltd. (URGN)? Levi & Korsinsky Urges Investors to Act Before July 28, 2025
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=153004&wire=1&utm_campaign=28 or contact Joseph E.
Read More
URGN CLASS ACTION ALERT: UroGen Pharma Ltd. Investors With Losses Are Notified to Contact BFA Law About The Securities Fraud Class Action Lawsuit
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ:URGN) and certain of the Company's senior executives for potential violations of the federal securities laws.
Read More
U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Published: June 12, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) approved ZUSDURI, the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC. ZUSDURI consists of mitomycin and sterile hydrogel, using UroGen's proprietary sustained release RTGel® technology. ZUSDURI has been designed.
Read More
The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – URGN
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN).
Read More
US FDA approves Urogen's bladder cancer drug
Published: June 12, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved Urogen Pharma's drug to treat a type of bladder cancer, the regulator said on Thursday.
Read More
Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025 - Contact Levi & Korsinsky
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152831&wire=1&utm_campaign=22 or contact Joseph E.
Read More
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102 - Hagens Berman
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
URGN Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / June 12, 2025 / A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd.
Read More
Class Action Alert: Levi & Korsinsky Reminds UroGen Pharma Ltd. (URGN) Investors of July 28, 2025 Deadline
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152672&wire=1&utm_campaign=17 or contact Joseph E.
Read More
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens Berman
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 11, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025.
Read More
Levi & Korsinsky Urges UroGen Pharma Ltd. (URGN) Shareholders to Act Before Lead Plaintiff Deadline July 28, 2025
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152657&wire=1&utm_campaign=18 or contact Joseph E.
Read More
Deadline Alert: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, June 11, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”).
Read More
Class Action Lawsuit Filed: UroGen Pharma Ltd. (URGN) - Join by July 28, 2025 - Contact Levi & Korsinsky
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152645&wire=1&utm_campaign=8 or contact Joseph E.
Read More
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Published: June 11, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , June 11, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the "Class Period"), have until Monday, July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit.
Read More
Securities Lawsuit Alert: UroGen Pharma Ltd. (URGN) Investors - Contact Levi & Korsinsky Before July 28, 2025
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152622&wire=1&utm_campaign=2 or contact Joseph E.
Read More
Securities Class Action Lawsuit Filed Against UroGen Pharma Ltd. (URGN) - Levi & Korsinsky Represents Shareholders
Published: June 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152462&wire=1&utm_campaign=13 or contact Joseph E.
Read More
About UroGen Pharma Ltd. (URGN)
- IPO Date 2017-05-04
- Website https://www.urogen.com
- Industry Biotechnology
- CEO Ms. Elizabeth A. Barrett
- Employees 234